Investigation of gastric cancer treatment using zolbetuximab

Investigation of gastric cancer treatment using zolbetuximab - Zolbetuximab Gastric Analysis 1

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060223

Enrollment

Registered

2025-12-28

Start date

2025-12-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with gastric cancer who have received chemotherapy

Exclusion criteria

Exclusion criteria: Patients judged ineligible for the study by the investigator

Design outcomes

Primary

Measure	Time frame
Protein expression of CLDN18.2, CDH1, and others in tumor tissues (From the date of IRB approval to March 31, 2027)	—

Secondary

Measure	Time frame
Correlation analysis between protein expression and patient characteristics (age, sex, metastatic organs) and clinical course, including retrospective cases.	—

Countries

Japan

Contacts

Public ContactShuhei Suzuki

Yamagata Prefectural Shinjo Hospital Internal Medicine

s-suzuki@med.id.yamagata-u.ac.jp0233-22-5525

Outcome results